Harbour BioMed has entered into a long-term global strategic collaboration and licence agreement with Bristol Myers Squibb (BMS) to jointly research and develop next-generation multispecific antibody therapies. Under the agreement, Harbour will receive payments totalling USD 90 million and is eligible for up to USD 1.035 billion in development and commercial milestone payments, plus tiered royalties on future net sales. This marks Harbour's third major multinational partnership in 2025.

The collaboration leverages Harbour's proprietary antibody technology platforms, particularly its HCAb (heavy-chain-only antibody) technology, which enables the flexible design of innovative multispecific molecules. The deal aligns with the company's strategic evolution towards deeper, platform-based global partnerships, as seen in earlier agreements with AstraZeneca and Otsuka Pharmaceutical.

PharmCube's NextBiopharm® database shows that Big Pharma acquisitions of China-developed multispecifics have accelerated this year. Click here to request a free trial for NextBiopharm®.